Fact: Price data from Yahoo Finance real-time quote. View live quote →
| Period | NXTC Return | S&P 500 |
|---|---|---|
| YTD | +52.78% | +10.28% |
| 1-Year | +36.73% | +20.43% |
| 3-Year | +68.28% | +67.56% |
| 5-Year | +92.43% | +72.59% |
Fact: Returns as of July 14, 2026 (Yahoo Finance). Interpretation: Recent surge driven by merger news dominates short-term performance; long-term reflects typical high-risk biotech volatility with significant drawdowns from 52-week high.
| Metric | Value |
|---|---|
| Revenue (TTM) | $0 (pre-commercial) |
| Net Income (TTM) | -$54.66M |
| EPS (TTM) | -$16.82 |
| Cash & Equiv. (mrq) | ~$29.74M |
| Market Cap | ~$24.2M (post-surge) |
| Enterprise Value | ~-18M |
Fact: No product revenue; consistent losses due to R&D. Cash runway previously projected into 2026-2027 (pre-merger). Interpretation: Typical for clinical-stage biotech; merger brings $320M PIPE which will significantly bolster balance sheet post-close.
| Consensus | Price Target |
|---|---|
| Strong Buy / Buy (3-5 analysts) | $19.33 avg (High: $25.00 | Low: $3.00-$15.00) |
Fact: Ratings and targets from Benzinga, Yahoo Finance, Marketscreener (3-5 analysts). Interpretation: Strong Buy reflects pipeline potential pre-merger; targets likely to be reassessed post-Avere deal and ticker change to AVRX.
Uncertainty: Limited analyst coverage for micro-cap; ratings may shift rapidly with merger completion (expected H2 2026).
Fact: Primarily R&D collaborations. Interpretation: No meaningful product sales customers yet.
| Company | Focus / Ticker | Market Cap (approx.) |
|---|---|---|
| Arch Biopartners | Biotech (ACHFF) | ~$41M |
| CytomX Therapeutics | ADCs / Oncology (CTMX) | ~$180M+ |
| Passage Bio | Gene therapy (PASG) | ~$200M+ |
| Other ADC/Immuno-oncology peers | Various small-caps | Variable |
Fact: Direct competitors in ADC/immuno-oncology space. Post-merger: IL-23 psoriasis competitors include AbbVie (Skyrizi), Johnson & Johnson, etc. Yahoo competitors →
Overview (Fact): NextCure, Inc. is a clinical-stage biopharmaceutical company (incorporated 2015, headquartered Beltsville, MD; ~40 employees) developing novel immunomedicines for cancer and immune-related diseases. Pipeline includes NC410 (LAIR-2 fusion), NC525 (LAIR-1 antibody), SIM0505 (CDH6 ADC in partnership), and others. Full profile →
History (Fact): Founded 2015; IPO ~2019; focused on restoring immune function in oncology. Key milestones include Fast Track designation for SIM0505 (ovarian cancer), ASCO 2026 data presentations, and prior equity raises. Recent pivot via Avere merger announced July 14, 2026.